Who is sponsoring NCT00435539?

NCT00435539 is sponsored by ThromboGenics.

What condition does NCT00435539 study?

NCT00435539 studies Vitreomacular Traction.

What drugs are being tested in NCT00435539?

Interventions: ocriplasmin, ocriplasmin, Sham Comparator.

What is the status of NCT00435539?

NCT00435539 is currently COMPLETED.

Last reviewed 2014-12-02 · How we verify

A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT).

NCT00435539 Phase 2 COMPLETED Results posted

A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.

Details

Lead sponsor	ThromboGenics
Phase	Phase 2
Status	COMPLETED
Enrolment	60
Start date	2007-02
Completion	2009-02

Conditions

Vitreomacular Traction

Interventions

ocriplasmin
ocriplasmin
Sham Comparator

Primary outcomes

Proportion of Subjects With Total PVD at the First Day 14 Post-injection Visit (Vitreous Detachment to the Equator) as Determined by Masked Central Reading Center (CRC) Evaluation of B-scan Imaging. — Day 14

Countries

Belgium, Germany